AlphaYou
Overview
Smart money at a glance
Filings to Sep 30, 2026Net selling: insiders sold $25.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$25.7M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 2 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 29- Open
- $289.13
- 52-wk high
- $303.31
- High
- $296.88
- 52-wk low
- $146.19
- Low
- $289.13
- Prev close
- $292.84
- Mkt cap
- $14.19B
- Volume
- 880.3K
- Fwd P/E
- 22.4x
- Beta
- 1.41
- P/S
- 3.5x
- P/B
- 4.7x
- Profit margin
- -6.0%
- Op margin
- +15.1%
- ROE
- -7.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about CRL filings
Are insiders buying or selling Charles River Laboratories (CRL) stock?
Net selling: insiders sold $25.7M and bought $0 of CRL stock on the open market in the 90 days to Sep 30, 2026, according to SEC Form 4 filings. $22.8M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Foster, James C (Director), who sold $18M. The latest filing was on Aug 27, 2026.
Which members of Congress have traded CRL recently?
None. No member of Congress disclosed a CRL trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this CRL smart-money data?
This summary uses filings available on Sep 30, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- SI
SRS Investment Mgmt
$42.5M
bought
- LA
Lakewood
$18.5M
added
Sells/Trims (1)
- DS
D.E. Shaw
$26.2M
trimmed
What insiders are doing
Sells (3)
- FJ
Foster James C
$10.1M
sold
- PS
Parisotto Shannon M
$600K
sold
- AN
Andrews Nancy C
$163K
sold
How top traders are positioned
No tracked top-trader positions in CRL right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 11.0% above what analysts expected.
Earnings per share
$2.72 expected
Reports Nov 4, 2026, in 35 days
Estimates as of Sep 30, 2026
EPS expected
$2.92 to $3.00
Revenue expected
9 analysts
Last 30 days
Analysts cutting estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.00B | $994.2M | $995.8M | $1.00B |
| Cost of what it sold | $666.1M | $686.4M | $716.5M | $640.7M |
| Gross profit | $338.8M | $307.9M | $279.3M | $363.4M |
| What it spent | ||||
| Sales and admin | $177.6M | $187.6M | $159.4M | $228.9M |
| Other operating costs | $27.4M | — | — | $14.6M |
| Total operating expenses | $205.0M | $187.6M | $159.4M | $243.5M |
| What was left | ||||
| Operating profit | $133.8M | $120.2M | $119.9M | $119.9M |
| Interest on debt | $25.4M | $23.8M | $26.7M | $30.3M |
| Profit before tax | $87.2M | -$294.1M | -$29.9M | $53.2M |
| Tax | $31.6M | -$17.8M | -$15.1M | $53.9M |
| Net profit | $54.4M | -$276.6M | -$14.8M | -$1.5M |
| EBITDA | $197.8M | -$192.0M | $64.0M | $150.8M |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating
Leans bullishSep 26Cambridge biotech co-founded by Alnylam founder Maraganore files for IPO
NeutralSep 26Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About?
Leans bullishSep 25AngloGold Ashanti Appoints Paul Graves as Independent Non-Executive Director
NeutralSep 25Mizuho raises Charles River Labs stock price target to $295 on outlook
Leans bullishSep 25Coca-Cola’s Secret Dividend Weapon Is a Business Model Most Investors Overlook
Leans bullishSep 25RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating
BullishSep 25Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating
Leans bullishSep 25
Macro
10 macro signals shaping CRL right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results